Drug intelligence / Profile preview

AMG 333

Development stage: Phase 1
Lead developer: Amgen
Modality: Small Molecules
Administration: Oral

Overview

AMG 333 is a potent and selective small molecule antagonist of the TRPM8 ion channel, which is the principal receptor responsible for the sensation of cold. It was developed by Amgen as a potential treatment for migraine. The drug demonstrates high selectivity for TRPM8 over other related channels and has shown activity in preclinical models relevant to migraine and cold-induced responses[1][5][7].

Other names: (S)-6-(((3-Fluoro-4-(trifluoromethoxy)phenyl)(3-fluoropyridin-2-yl)methyl)carbamoyl)nicotinic acidCHEMBL4241349CHEMBL-4241349CHEMBL 42413491416799-28-4

Targets

TRPM8 (Transient receptor potential cation channel subfamily M member 8)

Beyond the preview

Go deeper on AMG 333.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMG 333.

Explore the full profile